Experienced in Severe Congenital Neutropenia

Dr. Jose E. Sarriera

Hematology Oncology | Hematology | Oncology
Orlando Health Medical Group Inc
1400 S Orange Ave, 
Orlando, FL 
Accepting New Patients
Offers Telehealth
Experienced in Severe Congenital Neutropenia
Orlando Health Medical Group Inc
1400 S Orange Ave, 
Orlando, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jose Sarriera is a Hematologist Oncology specialist and a Hematologist in Orlando, Florida. Dr. Sarriera is rated as an Experienced provider by MediFind in the treatment of Severe Congenital Neutropenia. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma, Chronic B-Cell Leukemia (CBCL), and Bone Marrow Aspiration. Dr. Sarriera is currently accepting new patients.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in FL
Hospital Affiliations
Adventhealth Orlando
Orlando Health
Orlando Health St Cloud Hospital
Orlando Health South Lake Hospital
Orlando Health-Health Central Hospital
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Florida Blue
  • EPO
  • PPO
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

ORLANDO HEALTH MEDICAL GROUP INC
1400 S Orange Ave, Orlando, FL 32806

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Blinatumomab, Dasatinib, Mercaptopurine, Methotrexate, Methotrexate Sodium, Prednisone, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Enrollment Status: Suspended
Publish Date: September 05, 2025
Intervention Type: Biological, Drug, Procedure, Other
Study Drugs: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab
Study Phase: Phase 3
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2025
Intervention Type: Drug, Biological
Study Drugs: Rituximab, Bendamustine Hydrochloride, Bortezomib, Lenalidomide
Study Phase: Phase 2
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
Enrollment Status: Terminated
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drug: CG-806
Study Phase: Phase 1
Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
Enrollment Status: Terminated
Publish Date: August 18, 2022
Intervention Type: Drug
Study Drug: MT-3724
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

2 Total Publications

Successful Use of Adjunctive Red Blood Cell Exchange Therapy for Treatment of an Acute Hemolytic Reaction After ABO-Incompatible Red Blood Cell Transfusion.
Successful Use of Adjunctive Red Blood Cell Exchange Therapy for Treatment of an Acute Hemolytic Reaction After ABO-Incompatible Red Blood Cell Transfusion.
Journal: Journal of hematology
Published: July 05, 2019
Similar Doctors
Distinguished in Severe Congenital Neutropenia
Dr. Maen Hussein
Hematology | Oncology
Distinguished in Severe Congenital Neutropenia
Dr. Maen Hussein
Hematology | Oncology

Florida Cancer Specialists And Research Institute, LLC

1400 N Us Hwy 441 540, Florida Cancer Specialists, 
Lady Lake, FL 
 (45.7 miles away)
352-561-3290
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Maen Hussein is a Hematologist and an Oncologist in Lady Lake, Florida. Dr. Hussein is rated as a Distinguished provider by MediFind in the treatment of Severe Congenital Neutropenia. His top areas of expertise are Lung Cancer, Paget Disease of the Breast, Colorectal Cancer, and Myelodysplastic Syndrome (MDS).

Advanced in Severe Congenital Neutropenia
Dr. Sumeet Chandra
Oncology | Hematology Oncology | Hematology
Advanced in Severe Congenital Neutropenia
Dr. Sumeet Chandra
Oncology | Hematology Oncology | Hematology

Cancer Care Centers Of Brevard Inc

2290 W Eau Gallie Blvd, Suite 202, 
Melbourne, FL 
 (51.6 miles away)
321-254-4776
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Sumeet Chandra is an Oncologist and a Hematologist Oncology provider in Melbourne, Florida. Dr. Chandra is rated as a Distinguished provider by MediFind in the treatment of Severe Congenital Neutropenia. His top areas of expertise are Childhood Iron Deficiency Anemia, Familial Colorectal Cancer, Thrombocytopenia, and Colorectal Cancer. Dr. Chandra is currently accepting new patients.

Distinguished in Severe Congenital Neutropenia
Dr. Jennifer Cultrera
Oncology | Hematology
Distinguished in Severe Congenital Neutropenia
Dr. Jennifer Cultrera
Oncology | Hematology

Cora Health Services Inc

2953 Traverse Trl, 
The Villages, FL 
 (45.2 miles away)
352-693-3378
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jennifer Cultrera is an Oncologist and a Hematologist in The Villages, Florida. Dr. Cultrera is rated as a Distinguished provider by MediFind in the treatment of Severe Congenital Neutropenia. Her top areas of expertise are Paget Disease of the Breast, Lung Cancer, Vitamin B12 Deficiency, and Pleuropulmonary Blastoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sarriera's expertise for a condition
ConditionClose
    View All 12 Distinguished Conditions
    View All 33 Advanced Conditions
    View All 85 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile